MRI contrast developer Epix Pharmaceuticals said that the Australian Drug Evaluation Committee (ADEC) has recommended the firm's Vasovist blood pool imaging agent for approval in Australia.
Approval is subject to the finalization of labeling, according to the Cambridge, MA-based company.
By AuntMinnie.com staff writers
August 14, 2006
Related Reading
Epix grows revenues in Q2, August 7, 2006
FDA extends Epix's Vasovist appeal, July 31, 2006
Epix retains rights to EP-2104R, July 13, 2006
Epix files Vasovist appeal with FDA, July 4, 2006
Astrue resigns from Epix, May 8, 2006
Copyright © 2006 AuntMinnie.com
